Navigation Links
Celebrating 65 Years of Providing Superior Healthcare Products, Mission Pharmacal Continues to Thrive

SAN ANTONIO, Dec. 6, 2011 /PRNewswire/ -- For 65 years, Mission Pharmacal Company has remained true to the commitment of its founder H.N. Walsdorf to provide the highest quality healthcare medications and treatments available to consumers.  Even as the global economy continues to be uncertain, this Texas-based company remains steadfast in its loyalty to employees and consumers as it continues to search for more and better prescription and consumer products to add to its four expanding therapeutic areas of focus: women's health, urology, pediatrics, and dermatology.  This passion and fierce determination to provide treatments and therapies for a wide range of conditions and diseases have helped Mission Pharmacal grow to be a recognized leader in the pharmaceutical industry. 

Owned by the Walsdorf family, Mission proudly retains the founder's commitment to quality and innovation.  More than six decades of steady growth and consistent profitability have not shifted Mission's focus that starts with the selection of superior raw materials, continues through state-of-the-art manufacturing facilities, and finishes with product packaging that reflects the company's emphasis on patient well-being.

As a family-owned and family-run business, Mission Pharmacal truly recognizes the importance of meeting the market needs of families.  "When a mother is buying healthcare products for her family, we want her to look for the Mission Pharmacal label," says Neill Walsdorf Jr., president of Mission Pharmacal.  "And when she sees that label, we want her to know that she is holding a product of unquestioned effectiveness and unmatched quality.  We intend to keep pace with market needs, wherever that may lead us.  This is our commitment."

Mission Pharmacal extends this commitment to families and the community by partnering with other manufacturers and organizations to support community health programs and fund-raising efforts.  Mission Pharmacal is a proud national corporate sponsor of the March of Dimes Foundation and its March of Dimes March for Babies, its premier event.   

With corporate headquarters and manufacturing sites located in Texas, research and development facilities in Texas, and Vancouver, Washington, as well as a commercial office in the pharmaceutical hub of the Northeast corridor, Mission is strategically positioned to take advantage of opportunities in markets across the country.  Many of Mission's product lines are also distributed internationally.    

An established leader in women's health products, Mission Pharmacal offers a strong portfolio of prescription vitamins and therapies.  The CitraNatal® Family of Products offers a line of vitamin supplements specifically designed with comfort in mind to meet the specialized dietary needs of women who are pregnant or who are planning a pregnancy.  Formulated with proprietary high quality ingredients, CitraNatal is the number one selling prescription prenatal brand in the United States.  Ferralet®90 is an iron supplement featuring patented Ferr-Ease® dual iron to help minimize the gastric distress normally associated with iron therapies.  A second generation nitroimidazole, Tindamax® (tinidazole) is used for targeted treatment of bacterial vaginosis and certain parasitic infections, including trichomoniasis, giardiasis, and amebiasis.

Uribel® is another of the company's women's healthcare products and also falls into the urology therapeutic area.  This prescription medication helps relieve local discomfort and inflammation associated with lower urinary tract infections (UTIs), interstitial cystitis, painful bladder syndrome, and urinary tract procedures.

An acknowledged innovator in urology treatments, Mission Pharmacal offers a number of other products and therapies in this area as well, including Urocit®-K, an advanced medication used to effectively prevent the reoccurrence of kidney stones.  Since prevention is the best therapy, Thiola® provides a highly effective therapy to inhibit the formation of cystine kidney stones.  Sufferers of certain types of urinary infections resulting in struvite kidney stones, may not respond to other therapies such as antimicrobial agents, and may find Lithostat® to be a very successful course of action.   

Among Mission Pharmacal's pediatric care offerings is AsmalPred™, a pleasant tasting liquid prednisolone that is prescribed as a quick relief rescue medication for pediatric asthmatic events.  Dr. Smith's® Diaper Rash Ointment is an effective, non-prescription product for the treatment and prevention of diaper rash.

Just as Uribel is both a women's healthcare and urology product, Texacort®, a topical hydrocortisone used to treat swelling, itching, and redness of the skin caused by allergic reactions, eczema, psoriasis, or dermatitis is classified as both a pediatric and dermatological medication.

Mission Pharmacal continues to add new products to its drug and dietary supplement pipeline through utilizing its in-house research and development team of scientists in Boerne, Texas, and Vancouver, Washington.

The company's expertise in solid dose tablet manufacturing has earned it international manufacturing agreements, such as manufacturing Citracal® for Bayer Consumer Care and its affiliate companies.  Mission Pharmacal developed and patented the calcium citrate manufacturing process that allows a calcium supplement to be absorbed in the human stomach without the need for food and acid produced.  The Citracal line of products was sold to Bayer Consumer Care with the agreement that Mission would continue to make all formulas that carried the Citracal name under a long-term contract. 

The company's Boerne facility houses a progressive manufacturing operation that incorporates many advanced pharmaceutical production technologies.  Production processes are further enhanced through the use of innovative best practices and approaches that ensure both the quality of the products and the most efficient use of resources.  Mission Pharmacal is dedicated to ensuring that its production facilities remain among the most technologically-advanced and environmentally-friendly facilities in the world.

While proud of the legacy and vision of its founder, "to develop and manufacture pharmaceuticals with raw materials of superior quality to ensure the very best and most effective products," Mission Pharmacal looks enthusiastically to the future.  With a number of new drug development efforts in place with current and new service lines, along with plans to expand its partnership efforts with innovative companies both in the United States and overseas, the years ahead promise to be exciting and eventful for the company.  Mission Pharmacal expects to extend its offerings in women's health, urology, pediatrics, and dermatology while adding to its portfolio of consumer nutritional products and introducing new lines as appropriate.

Terry Herring, president of Commercial Operations for Mission Pharmacal, states, "Mission's growth and future continues to rest on our ability as a pharmaceutical company to anticipate and respond to the changing health needs of the world.  Our deep commitment to research and development, matched with our keen interest in providing superior products that meet these changing needs is key to our success."

About Mission Pharmacal

Mission Pharmacal is a privately held pharmaceutical company based in San Antonio, Texas.  For more than 65 years, the company has been committed to meeting the unique healthcare needs of women throughout all stages of life, pediatric patients, and those persons dealing with urologic and dermatologic conditions.  The company has a proven track record of identifying unmet healthcare needs and developing both innovative prescription and over-the-counter products to meet these needs.  Using only the purest ingredients, Mission Pharmacal provides physicians and consumers with the highest quality pharmaceutical and dietary supplement products on the market today.  Mission Pharmacal is a proud national supporter of the March of Dimes Foundation, whose mission is to improve the health of babies by preventing birth defects, premature birth, and infant mortality.  For more information about the company, visit


SOURCE Mission Pharmacal
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Regenicin to Present at Event Celebrating Advancements in Regenerative Medicine
2. MedNet Solutions Achieves the Inc. 5000 List Five Years in a Row
3. Thirty Years After 1st American "Test-Tube Baby," Economy May Be Biggest Obstacle for Infertile Couples
4. Martek Is Second Mtech Company Sold for More Than $1 Billion in Three Years
5. InspireMD Presents 2 Years Clinical Outcome of MGuard Multicenter Experience in STEMI Patients. The New Superb Clinical Results Were celebrated at InspireMDs TCT Satellite Symposium in Washington DC., Today.
6. CAS Chemistry Research Report: 40 Years of Biofuel Research Reveal China Now Atop U.S. in Patenting and Commercialization of Bioethanol
7. $1.1 Billion Invested in 183 Companies in the Cleveland Plus(TM) Region in the Past Five Years
8. Hertz Annual Appeal for Adult Congenital Heart Disease Center At UCLA Passes $2-Million Mark in Funds Raised Over Ten Years
9. Lancaster Laboratories -- First Lab to be A2LA Accredited for 30 Consecutive Years
10. Safety in Drinking Water? Monitoring for Radioactive Contaminants Only Required Every Three, Six, or Nine Years per Federal Law
11. 40 Years on the Leading Edge: Case Western Reserve Universitys Biomedical Engineering Department Commemorates Achievement, Looks to Future
Post Your Comments:
(Date:10/12/2017)... ... 12, 2017 , ... DuPont Pioneer and recently formed CasZyme, ... into a multiyear collaboration to identify and characterize novel CRISPR-Cas nucleases. The goal ... editing across all applications. , Under the terms of the agreement, Pioneer will ...
(Date:10/12/2017)... Diego, CA (PRWEB) , ... ... ... ( ) has launched Rosalindâ„¢, the first-ever genomics analysis platform specifically ... all bioinformatics complexity. Named in honor of pioneering researcher Rosalind Franklin, who ...
(Date:10/11/2017)... CA, USA (PRWEB) , ... October 11, 2017 , ... ... to take place on 7th and 8th June 2018 in San Francisco, CA. The ... influencers as well as several distinguished CEOs, board directors and government officials from around ...
(Date:10/11/2017)... ... October 11, 2017 , ... Disappearing forests and increased emissions are ... 5.5 million people each year. Especially those living in larger cities are affected by ... in one of the most pollution-affected countries globally - decided to take action. , ...
Breaking Biology Technology:
(Date:4/5/2017)... 2017 KEY FINDINGS The global ... a CAGR of 25.76% during the forecast period of ... factor for the growth of the stem cell market. ... MARKET INSIGHTS The global stem cell market is ... geography. The stem cell market of the product is ...
(Date:3/30/2017)... March 30, 2017 Trends, opportunities and forecast ... behavioral), by technology (fingerprint, AFIS, iris recognition, facial recognition, ... others), by end use industry (government and law enforcement, ... and banking, and others), and by region ( ... Asia Pacific , and the Rest ...
(Date:3/24/2017)... Research and Markets has announced the addition ... Trends - Industry Forecast to 2025" report to their offering. ... The Global Biometric ... of around 15.1% over the next decade to reach approximately $1,580 ... market estimates and forecasts for all the given segments on global ...
Breaking Biology News(10 mins):